Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox; Laia Monserrat; Meritxell Bellet; Guillermo Villacampa; Abel Gonzalez-Perez; Mafalda Oliveira; Fara Brasó-Maristany; Nusaibah Ibrahimi; Srinivasaraghavan Kannan; Leonardo Mina; Maria Teresa Herrera-Abreu; Andreu Òdena; Mònica Sánchez-Guixé; Marta Capelán; Analía Azaro; Alejandra Bruna; Olga Rodríguez; Marta Guzmán; Judit Grueso; Cristina Viaplana; Javier Hernández; Faye Su; Kui Lin; Robert B Clarke; Carlos Caldas; Joaquín Arribas; Stefan Michiels; Alicia García-Sanz; Nicholas C Turner; Aleix Prat; Paolo Nuciforo; Rodrigo Dienstmann; Chandra S Verma; Nuria Lopez-Bigas; Maurizio Scaltriti; Monica Arnedos; Cristina Saura; Violeta Serra

doi:10.1038/s41467-022-34580-3

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer

Nat Commun. 2022 Nov 14;13(1):6928. doi: 10.1038/s41467-022-34580-3.

Authors

Marta Palafox¹, Laia Monserrat¹, Meritxell Bellet^{2

3}, Guillermo Villacampa⁴, Abel Gonzalez-Perez^{5

6}, Mafalda Oliveira^{2

3}, Fara Brasó-Maristany⁷, Nusaibah Ibrahimi^{8

9}, Srinivasaraghavan Kannan¹⁰, Leonardo Mina¹¹, Maria Teresa Herrera-Abreu¹², Andreu Òdena¹, Mònica Sánchez-Guixé¹, Marta Capelán^{2

3}, Analía Azaro^{2

3}, Alejandra Bruna¹³, Olga Rodríguez¹, Marta Guzmán¹, Judit Grueso¹, Cristina Viaplana⁴, Javier Hernández¹⁴, Faye Su¹⁵, Kui Lin¹⁶, Robert B Clarke¹⁷, Carlos Caldas¹⁸, Joaquín Arribas^{19

20

21

22

23}, Stefan Michiels^{8

9}, Alicia García-Sanz¹¹, Nicholas C Turner¹², Aleix Prat^{7

24

25

26

27}, Paolo Nuciforo²⁸, Rodrigo Dienstmann⁴, Chandra S Verma^{10

29

30}, Nuria Lopez-Bigas^{5

6

23}, Maurizio Scaltriti³¹, Monica Arnedos^{32

33}, Cristina Saura^{2

3}, Violeta Serra^{34

35}

Affiliations

¹ Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
² Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
³ Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain.
⁴ Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁵ Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
⁶ Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain.
⁷ Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
⁸ Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.
⁹ Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France.
¹⁰ Bioinformatics Institute (A*STAR), Singapore, Singapore.
¹¹ Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
¹² The Breast Cancer Now Research Centre, London, UK.
¹³ Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research, London, UK.
¹⁴ Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
¹⁵ Novartis Pharmaceuticals, East Hanover, NJ, USA.
¹⁶ Genentech, Inc., South San Francisco, California, USA.
¹⁷ Breast Biology Group, Manchester Breast Centre, Manchester, UK.
¹⁸ Cancer Research UK, Cambridge, UK.
¹⁹ CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
²⁰ Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
²¹ Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.
²² IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
²³ Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
²⁴ University of Barcelona, Barcelona, Spain.
²⁵ Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
²⁶ SOLTI Breast Cancer Research Group, Barcelona, Spain.
²⁷ Department of Oncology, IOB Institute of Oncology, Barcelona, Spain.
²⁸ Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
²⁹ School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
³⁰ Department of Biological Sciences, National University of Singapore, Singapore, Singapore.
³¹ Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA.
³² Department of Medical Oncology, Gustave Roussy, Villejuif, France.
³³ Inserm Unit U981, Villejuif, France.
³⁴ Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. vserra@vhio.net.
³⁵ CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain. vserra@vhio.net.

No abstract available

Publication types

Published Erratum

Publication types

Grants and funding